Amantadine in treatment of chronic hepatitis C virus infection?
Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy
Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy
Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response
Clinical usefulness of total hepatitis C virus core antigen quantification to monitor the response to treatment with peginterferon alpha-2a plus ribavirin*
Telomerase reverse transcriptase mRNA expression in peripheral lymphocytes of patients with chronic HBV and HCV infections
Interferon reduces somatic mutation of mitochondrial DNA in liver tissues from chronic viral hepatitis patients
Interferon-α suppresses liver cell proliferation in patients with chronic hepatitis C virus infection
Flow cytometry of fine-needle-aspiration biopsies
Hepatic necroinflammation and fibrosis in patients with genotypes Ba and C, core-promoter and precore mutations
Polymorphisms of the renin–angiotensin system and the severity of fibrosis in chronic hepatitis C virus infection
Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection
Weight loss during pegylated interferon and ribavirin treatment of chronic hepatitis C*
Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C
Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments
Changes in epidemiological patterns of HCV infection and their impact on liver disease over the last 20 years in Greece